You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
The firm said that the proceeds will be used to complete the development of the Cue Health Monitoring System and Cue Test Cartridges.
The technologies, called non-extensible oligonucleotides and linear DNA assembly, may help the sample prep firm improve existing products.
The cancer test developer will use the funding to commercialize its enrichment-based NGS panels. An IVD test also got CE marked.
Researchers have developed a smartphone-powered device that can identify DNA in various sample types, New Scientist reports.
The platform's portability and internet connectivity could enable it to locate and track the distribution of disease in real time, its developers said.
The firms have entered into a strategic partnership to integrate their respective amplicon-based target enrichment technologies for use in NGS testing.
The firm's whole-genome amplification chemistry may help researchers better understand cancer heterogeneity, even between cells.
The Durham, North Carolina-based startup will use the funds to develop a library preparation kit for single-cell sequencing.
Functional enhancers can accompany oncogenes on the circularized extrachromosomal amplicons found in glioma and other tumors, enhancing cancer growth.
The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.
The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.
Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.
In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.